Get up-to-date information on products and services during 30 min. sessions.
These non-CME symposia are developed independently by industry—they are not affiliated with the official program of AAO 2022 or Subspecialty Day
Industry Showcases are not broadcast in the virtual meeting, nor will they be recorded for future viewing.
Booth 1026
Saturday, Oct. 1
10:10 a.m.
A First-Line Treatment Option for Diabetic Macular Edema
Presenter: Sri Mukkamala, MD
Learn about the management of diabetic macular edema. Consider the role of anti-VEGF treatment and a first-line treatment option. Understand patient support options available to patients.
Presented by Regeneron
11:10 a.m.
Discover Hidden Signs When You ‘Look at the Lids’
Presenters: Richard A. Adler MD, FACS and Dagny Zhu, MD
Approximately 25 million Demodex blepharitis patients exist in the US and 80% still seek treatment. Discuss the signs you may find when you ‘Look at the Lids.’
Presented by Tarsus Pharmaceuticals, Inc.
12:10 p.m.
Through the Experience of a Neuro-ophthalmologist: Early Diagnosis, Referral, and Treatment of Thyroid Eye Disease (TED) with TEPEZZA® (teprotumumab-trbw)
Presenter: Robert Sergott, MD
Presented by Horizon Therapeutics
1:10 p.m.
A First-Line Treatment Option for Wet Age-Related Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy
Presenter: John Kitchens, MD
Learn about the management of common retinal diseases. Consider the role of anti-VEGF treatment and a first-line treatment option. Understand patient support options available to patients.
Presented by Regeneron
2:10 p.m.
Realizing Our Vision - Novartis’ Commitment to Ophthalmology
Presenters: Jill Hopkins, MD and Randall “Randy” Wong, MD
An overview of Novartis' commitment to ophthalmology and highlights of relevant disease states of interest.
Presented by Novartis Pharmaceuticals Corporation
3:10 p.m.
Vabysmo: The First and Only Dual Pathway Inhibiting Therapy in nAMD & DME
The Power of Two - Learn more about a new treatment for age-related macular degeneration (nAMD) and diabetic macular edema (DME).
Presented by Genentech, Inc.
4:10 p.m.
Access and Reimbursement Primer for Early Career Retinal Specialists
Presenter: Eric Goldstein, Sr. Director Market Access Strategy
Explore navigating access and reimbursement for anti-VEGF treatment. Understand the evolving anti-VEGF market access landscape.
Presented by Regeneron
Sunday, Nov. 14
10:10 a.m.
A First-line Treatment Option for Macular Edema Following Retinal Vein Occlusion
Presenter: Seenu Hariprasad, MD
Learn about the management of Macular Edema following Retinal Vein Occlusion. Consider the role of anti-VEGF treatment and a first-line treatment option. Understand patient support options available to patients.
Presented by Regeneron
11:10 a.m.
Biosimilars: Increasing Choice in the Marketplace
Presenter: Peter Kaiser, MD
Join us for an exciting look into the world of biosimilars. Learn about these promising therapeutic options and their potential to expand patient access to cost-effective treatment.
Presented by Coherus BioSciences, Inc.
12:10 p.m.
Eyeing Up Evaporation: Getting at the Heart of Dry Eye Disease
Presenters: Preeya K. Gupta, MD and Kenneth A. Beckman, MD, FACS
Focused discussion around the etiology and key drivers of dry eye disease. Learn how various intrinsic and extrinsic factors affect evaporation rates and patient symptoms.
Presented by Bausch + Lomb
1:10 p.m.
A First-Line Treatment Option for Diabetic Retinopathy
Presenter: David Almeida, MD
Learn about the management of diabetic retinopathy. Consider the role of anti-VEGF treatment and a first-line treatment option. Understand patient support options available to patients.
Presented by Regeneron
2:10 p.m.
Health System Adoption of Autonomous AI Technology for Diabetic Retinopathy Screening in Primary Care
Presenters: Jeffrey D. Henderer, MD; Steven Yeh, MD; and Eric D. Hansen, MD
Presented by Eyenuk, Inc.